Juvisync Type 2 Diabetes Drug and Cancer

Juvisync side effects may include pancreatic cancer. Studies show an association between one of the two active medications in this type 2 diabetes drug and cancer. The U.S. Food and Drug Administration (FDA) is investigating a possible increased pancreatic cancer risk.

What is Juvisync?

Approved by the FDA in October 2011, Juvisync is the first fixed-dose combination medication prescribed to treat type 2 diabetes and high cholesterol in one pill. Juvisync, manufactured by Merck, includes the active drugs sitagliptin and simvastatin. Simvastatin is a statin approved to reduce low-density lipoprotein (LDL) cholesterol in the blood.

About Sitagliptin & the Pancreatic Cancer Risk

Sitagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor. DPP-4 is a digestive enzyme that breaks down hormones called incretins. By inhibiting DDP-4, sitagliptin prohibits the degradation of incretin hormones and prolongs their action, enhancing the body’s ability to lower high blood sugar levels.

However, apparently this enzyme is also one of the body’s natural defenses against cancerous tumors. That means inhibiting DPP-4 could also hinder the body’s ability to suppress cancer.

Post-marketing reports indicate sitagliptin is associated with an increased risk for pancreatitis. Risk factors for pancreatitis can also be risk factors for pancreatic cancer.

Sitagliptin is in a class of drugs called incretin mimetics. The FDA is now reviewing findings from a research group showing an association between these type 2 diabetes drugs and pancreatic cancer. Read more about sitagliptin and cancer.

Sitagliptin was first marketed under the brand name Januvia, approved by the FDA in 2006. Other brand names include Janumet and Janumet XR.

Juvisync Pancreatic Cancer Lawsuit

If you or a family member were diagnosed with pancreatic cancer after taking Juvisync, you are encouraged to talk with an experienced pharmaceutical injury lawyer about your potential claim against the drugmaker.

The mass tort law firm Watts Guerra LLP is handling the largest incretins pancreatic cancer injury and wrongful death docket in the country. Our firm has successfully represented clients against some of the largest and most powerful pharmaceutical companies, resulting in better patient safety in addition to substantial settlements and verdicts.

Lawyers of Watts Guerra LLP review pancreatic cancer cases related to Juvisync and other type 2 diabetes drugs nationwide. Contact them now for a free case review.

Disclaimer: The images on this page of the Victoza packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Norvo Nordisk.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

More Information

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.
Contact us using our online form, or call us toll-free at 1(800)796-9605.